Munich Startup
Coastal Biotech

Coastal Biotech

Coastal Biotech connects biochemistry and biosciences by integrating biological principles into technological advances and materials derived from marine organisms and resources. Our bio-based technology uses marine organisms such...

Founded2026
Business ModelB2B
IndustryBioTech
This content was machine translated.

About Coastal Biotech

Coastal Biotech connects biochemistry and biosciences by integrating biological principles into technological advances and materials derived from marine organisms and resources. Our bio-based technology uses marine organisms such as algae and bacteria as a source for enzymes, biomaterials, bio-based chemical raw materials, and other biologically active, high-quality molecules that enable applications toward environmentally friendly transitions in current areas of product development where the fundamental ingredients are based on fossil fuels or unsustainable chemicals or dependencies on fossil fuel-based ingredients. Currently, our green transition in chemicals and fossil fuels is rooted in the basis of food consumption—in agriculture, where the production of biostimulants offers alternative pathways and addresses some of the urgent ecological challenges of our society: climate protection and adaptation as well as the transition to a more circular, resilient economy and green industry. Our concept, oriented toward a production model, sees the manufacture of bio-based products as an opportunity for strategic autonomy and resilience near our locations by reducing dependence, including import dependence, on fossil resources such as petroleum, chemical ingredients such as fertilizers, cosmetics, paints, lubricants and adhesives, and many other application areas.

More like this

Discover relevant articles, startups, and events from the ecosystem

EpiCure

EpiCure is a research project of Ludwig Maximilians University Munich and is scheduled to be incorporated as an independent biotech company in 2026/2027. The focus is on epigenetic therapies, a mechanism of action that still holds considerable untapped potential in oncology. The lead compound is Carbacitabin (CAB), a drug molecule rationally designed on the basis of epigenetic expertise for blood cancer diseases, primarily positioned for high-risk patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). CAB was specifically developed to address the weaknesses of clinically used standard therapeutics, and achieves approximately 100-fold reduced toxicity in patient-derived tumor models while simultaneously demonstrating superior efficacy. The regulatory foundation is in place: The BfArM has confirmed the preclinical development program in Scientific Advice. The first clinical trial is planned for 2027/28.

B2BBioTech

2026Founded
-Team size
Seed stage

ProviGenAI

ProviGenAI develops a software platform for automated experiments and data-driven process optimization. Many laboratories and biotechnology development environments already have extensive automation in place, yet the planning, evaluation, and adaptation of experiments continues to be done manually. Our platform combines automated laboratory workflows with AI-based optimization. It translates experimental protocols into executable workflows, orchestrates experiments on existing automation systems, and analyzes the resulting data to continuously improve parameters. This creates closed learning loops between experiment, analysis, and decision-making. Teams can optimize biotechnological processes—such as fermentation, screening, or bioprocess development—significantly faster and more efficiently.

B2BBioTech

2026Founded
-Team size
Seed stage